WillItSurvive
Medical technology and health companies · United States

Agilent Technologies

agilent.com ↗

Makes lab instruments (mass spec, chromatography) and diagnostics tools for research and clinical labs.

Hard to displace
Assessed 22 July 2026 · Evidence as of 22 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 22 July 2026 · Checkable from August 18, 2026 · Every call on the record Checkpoint: Q3 FY2026 earnings report
The call

Agilent sits inside a stable, regulated instrument oligopoly with Thermo Fisher and Danaher, and it is folding AI into its own products rather than losing ground to them.

Agilent makes machines and chemicals that labs use to test and analyze samples, along with software to run them. Once a lab buys their equipment, switching to a rival like Thermo Fisher or Waters is hard because the machines, software, and test kits all work together, and regulators have already approved that specific combination for medical use. Agilent also sells replacement chemicals and services year after year, which brings in predictable money. Agilent itself is adding artificial intelligence tools to make its equipment smarter, so AI is making the company stronger, not weaker. The main risks are slower sales in China right now and whether new tariffs on semiconductors in 2027 will hurt costs; neither one threatens the core business.

Why
01
AI pressure: None apparent. AI needs Agilent's hardware to run; Agilent bakes AI into its own instruments like the xCELLigence eSight rather than being replaced by it. Could AI do the core job? Unlikely.
02
Bigger players: Thermo Fisher Scientific. Thermo Fisher competes head to head in mass spec and chromatography but has not displaced Agilent's installed base or share position. Could a giant copy it? No, they are blocked.
03
What protects it. Labs run regulated workflows on Agilent-specific hardware, software, and chemistry, plus recurring CrossLab consumables and service contracts that are costly to rip out.
What would change this call
Thermo Fisher or Danaher reporting mass spec/chromatography share gains vs Agilent in quarterly filings. Would indicate a core peer is displacing Agilent's installed base, not just competing.
Agilent's China revenue trend and commentary in Q3 FY2026 earnings (August 18, 2026). Shows whether China softness is deepening or recovering, affecting growth base.
Biocare Medical EPS-accretion milestone update around mid-2027. Confirms whether the diagnostics acquisition is integrating successfully as planned.
Key numbers
  • FY2025 revenue $6.95B, up 6.7% reported (2025-10-31)
  • Market cap approximately $37.5B (2026-07-22)
  • Biocare Medical acquisition closed for ~$950M (2026-06-25)
Named risks
  • China end-market softness combined with mid-August 2026 US-China tariff truce expiry risk. Severity: medium
  • Section 301 tariff investigations and proposed 10-12.5% forced-labor tariff (June 2, 2026) raising cost pressure. Severity: medium
  • Biocare Medical integration execution risk ahead of ~12-month EPS-accretion target (mid-2027). Severity: low
  • Cyclicality of instrument-replacement-cycle demand tailwind proving temporary. Severity: medium
  • Weakness in food and academia/government end-markets flagged for FY2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Thermo Fisher ScientificcontestingLong-standing top-2 peer in mass spec and chromatography, no displacement evidence as of 2026
Danaher CorporationcontestingDiversified conglomerate rival adjacent in diagnostics via Beckman Coulter, Cytiva, Leica Biosystems
Waters CorporationcontestingCited as a principal participant alongside Agilent and Thermo Fisher in pharma mass spectrometry, 2026
Bruker CorporationcontestingSmaller rival in mass spectrometry and instrumentation categories, no share-shift evidence found
Questions people ask
Is Agilent Technologies profitable in 2026?
Yes. Agilent posted FY2025 revenue of $6.95 billion (up 6.7% reported, ended Oct 31, 2025) and raised FY2026 guidance on May 27, 2026 to $7.39-7.49 billion revenue with non-GAAP EPS of $6.00-$6.10, signaling continued profitability.
Could AI replace Agilent Technologies?
No. Agilent's business is hardware, consumables, and regulated-service revenue tied to installed mass spec and chromatography instruments. It launched its own AI module, xCELLigence eSight AI, on July 1, 2026, absorbing AI as a bundled feature rather than being disrupted by it.
Who is Agilent's biggest competitor?
Thermo Fisher Scientific is Agilent's largest and longest-standing peer, competing category by category across mass spectrometry and chromatography for over 20 years. Danaher and Waters Corporation are also cited as principal rivals in life-science instrumentation as of 2026.
Who owns Agilent Technologies?
Agilent is a stand-alone public company (NYSE: A) with no parent entity. It was spun off from Hewlett-Packard in 1999 via a $2.1 billion IPO, then itself spun off Keysight Technologies in 2014.
Is Agilent Technologies growing in 2026?
Yes. Q2 FY2026 (ended Apr 30, 2026) revenue rose 10.0% reported (6.3% core) to $1.83-1.84 billion, prompting management to raise full-year FY2026 revenue guidance to $7.39-7.49 billion on May 27, 2026.
Did Agilent Technologies acquire Biocare Medical?
Yes. Agilent agreed to acquire pathology diagnostics firm Biocare Medical in March 2026 for approximately $950 million and completed the deal on June 25, 2026; Biocare had reported sales above $90 million the prior year.
Timeline
  • 2026-08-18Q3 FY2026 earnings report scheduled (confirmed as of 2026-07-14)
  • 2026-07-01Launched xCELLigence RTCA eSight AI, an AI-powered cell-image analysis module
  • 2026-06-25Closed ~$950M acquisition of Biocare Medical, adding IHC/ISH/FISH capabilities
  • 2026-05-26Reported Q2 FY2026 revenue of $1.83-1.84B, up 10% reported; raised FY2026 guidance
  • 2026-03Agreed to acquire Biocare Medical (deal later closed June 2026)
  • 2026-02-24Reported Q1 FY2026 revenue of $1.80B, up 7.0% reported / 4.4% core
  • 2025-11-24Reported Q4 and full FY2025 revenue of $6.95B, up 6.7% reported
  • 2014Spun off Keysight Technologies as a separate public company
  • 1999Founded as spinoff of Hewlett-Packard via $2.1B IPO, largest in Silicon Valley history
Head to head
Agilent Technologies vs Bio-Techne Corporation
Revision history
22 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Epic SystemsPro MedicusCochlear Limited
More in Medical technology and health companies →
Sources